ArticleDiscover oncology2025
VAMP5 promotes glioma progression through bioinformatics analysis clinical correlation and functional validation.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundGlioma is the most common and aggressive primary brain tumor, characterized by high heterogeneity, invasive growth, and poor prognosis. Identifying novel molecular drivers is essential for improving diagnosis, prognosis, and treatment. This study aimed to investigate the expression pattern, clinical significance, and functional role of VAMP5 in glioma.
methodsThis study integrated data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets, and systematically evaluated VAMP5 expression in glioma, with validation performed via Real-time PCR, immunohistochemistry, and Western blot. Meanwhile, we analysed the prognostic value, clinicopathological features, function enrichment analysis, immune cell infiltration relevance of VAMP5. Subsequently, in vitro and in vivo experiments were conducted to further validate the role and mechanism of VAMP5 in glioma.
resultsVAMP5 was significantly upregulated in glioma tissues compared to normal brain tissue across multiple datasets and clinical samples. Single-cell RNA sequencing (scRNA-seq) further confirmed distinct distribution heterogeneity of VAMP5 within glioma cells. A protein-protein interaction (PPI) network was constructed to identify key hub genes, combined with pathway enrichment analysis and immune infiltration profiling to decipher VAMP5-mediated mechanisms in glioma progression. Finally, functional assays in GBM cell lines were conducted to illustrate the molecular mechanisms underlying VAMP5-mediated promotion of GBM progression. In vitro and in vivo experiments further validated that VAMP5 promotes the proliferation and migration of glioma.
conclusionVAMP5 promotes glioma progression and is associated with immune modulation and adverse clinical outcomes. It may serve as a novel biomarker for prognosis and a potential therapeutic target in glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.